Complete turn-key solution for the judicious clinical laboratory owner.
MARKET INSIGHT
Our knowledge of the laboratory market and its unprecedented level of change can help guide the judicious clinical laboratory owner to mitigate reimbursement challenges, pursue emerging opportunities, and employ solutions to secure bottom line financial performance.
EXPERTISE
We work with senior management to setup/startup the most profitable clinical laboratory for your patient or client base. We help plan, design, implement, and optimize every element of your operation, as we provide on-going support to ensure each solution employed delivers long lasting value.
PARTNERSHIP
If you desire, after we setup/startup your laboratory, we will serve as your exclusive clinical laboratory advisor to oversee and manage the technical and scientific operations of your laboratory with a focus on optimizing data quality and profitability over time.
WE SPECIALIZE IN THE SETUP/STARTUP OF CLINICAL LABORATORIES
Our areas of expertise are molecular (PGx, CGx, RPP and COVID), general health, urine TOX screen/confirm, and cannabis.
As we make every effort to earn your trust by focusing on data quality and optimal financial performance, our market insight and clinical laboratory expertise will be of great value to your decision-making going forward.
Trusted Advisor - Complete Turn-Key Solutions
Medical Source is structured to assist the judicious clinical laboratory owner in selecting the most appropriate solutions available to ensure the highest data quality, lowest reportable costs, and fastest turnaround times.
We have relationships with the premier solution providers in the clinical laboratory setting and the experience, expertise, and market insight to guide you though this complex process.
We specialize in molecular, urine toxicology, general health, and cannabis. We help facilitate the entire laboratory project and actualize the results you desire.
- Molecular PGx
- Molecular CGx
- Molecular Respiratory Pathogen Panel and COVID
- Urine Toxicology Screening and Confirmations
- General Health and Comprehensive Wellness
- Cannabis
PGx - Pharmacogenomic Testing for Drug Metabolism
Drug efficacy and toxicity vary substantially across individuals.
Drugs and dosages are typically adjusted by trial and error. The clinical consequences include prolonged time to optimal therapy and/or adverse drug reactions, which account for the injury or death of more than 770,000 people each year.
PGx (Pharmacogenomic testing) presents a solution to reduce health care costs associated with ADRs and poor response to pharmacotherapy. The patient’s genetic makeup in combination with other clinical information creates a personalized medication regimen with greater efficacy and safety. Most prescribed medications have genetic data to support appropriate dosing or selection, as these analyses are routinely performed during drug development.
CARDIOLOGY PROFILE
* APOE - CYP1A2 - CYP2C19 - CYP2C9 - CYP2D6 - CYP3A4 - CYP3A5 - Factor II - Factor V - MTHFR - SLC01B1 - VKORC1 *
ONCOLOGY PROFILE
* CYP2D6 - CYP3A4 - DPYD - MTHFR - SLC01B1 - TPMT *
PAIN PROFILE
* CYP1A2 - CYP2C19 - CYP2C9 - CYP2D6 - CYP3A4 - CYP3A5 - MTHFR *
PSYCHIATRY PROFILE
* CYP2D6 - CYP2C19 - CYP1A2 - CYP2C9 - MTHFR - TPMT- CYP3A4 - CYP3A5 *
CGx - Cancer Genomics - Inherited (Hereditary) Cancer
CGX – Cancer Genomics - Inherited (Hereditary) Cancer Testing provides physicians the ability to refine a patient’s cancer risk through an analysis of inherited mutations.
Approximately 5 to 10 percent of cancers are thought to be caused by mutations in genes associated with hereditary cancer syndromes. Providing pertinent information about cancer risk is important to a patient’s understanding and ability to make informed decisions regarding their healthcare.
BREAST PROFILE
* BRCA1 - BRCA2 -TP53 - PTEN - STK11 - CDH1 - PALB2 - CHEK2 - ATM - NBN - BARD1 - BRIP1 *
OVARIAN PROFILE
* BRCA1 - BRCA2 - MLH1 - MSH2 - MSH6 - PMS2 - EPCAM - TP53 - STK11 - PALB2 - BARD1 - BRIP1 - RAD51C - RAD51D *
UTERINE PROFILE
* MLH1 - MSH2 - MSH6 - PMS2 - EPCAM - TP53 - PTEN - STK11 *
COLORECTAL PROFILE
* MLH1 - MSH2 - MSH6 - PMS2 - EPCAM - APC - MUTYH - TP53 - PTEN - STK11 - BMPR1A - SMAD4 - PALB2 - ATM *
PANCREATIC PROFILE
* CHEK2 - BRCA1 - BRCA2 - MLH1 - MSH2 - EPCAM - APC - CDKN2A - TP53 - STK11 - BMPR1A - SMAD4 - PALB2 - ATM *
LYNCH SYNDROME PROFILE
* MLH1 - MSH2 - MSH6 - PMS2 - EPCAM *
RPP - Respiratory Pathogen Panel and COVID
Report results 8 hours after sample extraction.
TARGETED AND SYNDROMIC MOLECULAR TESTING FOR RESPIRATORY INFECTION IS MORE IMPORTANT TODAY THEN EVER BEFORE DUE TO THE ONSET OF COVID 19
Testing for respiratory pathogens has always been important because of the significant overlap of symptoms across infections, but with the onset of COVID 19, identifying the RNA to confirm the virus and/or testing for the Covid 19 antibodies has taken center stage.
Our solution for COVID 19 ensures you deliver the highest-quality data. The novel method is very sensitive, capable of detecting minute amounts of the virus in samples obtained by nasal swab, and eliminates the use of fluorescent markers, reducing the need for costly reagents and avoiding potential supply chain issues.
URINE TOXICOLOGY - SCREENING & CONFIRMATION
OUR UNIQUE VALUE TO EACH CLIENT
*
METHODS TO DETECT NEW EMERGING DRUGS
Many drugs such as Carfentanyl, Kava Kratom, and various forms of synthetic marijuana like K2, Spice, Bath Salts, AK-47, and 24 Karat Gold are difficult to detect. Medical Source and our strategic partners in the academic, state, and commercial marketplace remain vigilant to incorporate methods for their identification into your clinical laboratory.
URINE DRUG TESTING provides objective information to identify the presence or absence of drugs or drug classes in the body and assists in making treatment decisions.
Specimen Validity Testing - to ensure the sample is consistent with normal human urine and has not been adulterated or substituted; may include pH, specific gravity, oxidants, and creatinine.
Presumptive / Qualitative Drug Testing - to determine the presence or absence of drugs or drug classes in a human sample; results are expressed as negative, positive, or as a numerical result.
Definitive / Quantitative Drug Testing - to identify specific medications, illicit substances, and metabolites; reports the results of drugs absent or present in concentrations of ng/ml; payment is limited to LC/MS methodology.
GENERAL HEALTH STATUS
As payers transition to payments based on outcomes or episodes of care, it is critically important to document scientific evidence of improved patient outcomes in the clinical record.
CLINICAL LABORATORY DATA FORMS THE SCIENTIFIC BASIS UPON WHICH MEDICAL DECISIONS ARE MADE AND MEDICAL DIAGNOSIS AND MANAGEMENT OF PATIENTS IS ESTABLISHED.
Clinical laboratory data is essential to:
* formulate and confirm clinical diagnoses
* monitor metabolic and organ function
* monitor therapeutic drug levels
* monitor results of medical treatment
CANNABIS TESTING
Cannabis laboratories face the challenge of delivering cost effective, high quality data, while meeting the requirements of constantly evolving and emerging state regulations.
Medical Source offers world class cannabis and hemp analysis hardware, software, and consumable solutions, specifically configured to meet the demanding requirements of the rapidly evolving marketplace. Our experience and expertise in the clinical laboratory can help you actualize the results you desire.
* Potency
* Pesticides and mycotoxins
* Terpines
* Heavy metals and nutrients
* Residual Solvents
* Microbial